Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
PHASE2
The primary objective of this trial was to establish non-inferiority of lun...
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
PHASE3
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 m...
Status
Completed
Location
205.419.01058 Boehringer Ingelheim Investigational Site
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
PHASE3
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µ...
Status
Completed
Location
205.464.81020 Boehringer Ingelheim Investigational Site
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
PHASE3
The overall objective is to assess the effect of once daily tiotropium + ol...
Status
Completed
Location
1237.19.10039 Boehringer Ingelheim Investigational Site
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
PHASE2
The primary objective of this trial is to evaluate the safety and efficacy ...
Status
Completed
Location
205.443.12003 Boehringer Ingelheim Investigational Site